276MS, Scientist, Computational Biology

Job Code 276MS


Fate Therapeutics is currently seeking a talented and motivated Scientist-Computational Biology professional with software development experience to join our Computational Biology team. This position offers the opportunity to participate in development and application of innovative, sophisticated computational methods and tools for data analysis; perform end-to-end data analysis, visualization, and interpretation of data from NGS platforms. The successful candidate will integrate tools into an internal web-based platform for use by Fate scientists and will work closely with Fate’s bench-scientists to assist in the experimental design and analysis of data sets to fully characterize Fate’s novel iPSC-derived cellular therapy products and clinical patient samples from our current and future clinical trials. The successful candidate must have extensive experience working with NGS-based analysis algorithms, workflows and pipelines. Candidate must be highly proficient in programming and scripting languages such as Python and R. This is a full-time position reporting to the Senior Manager, Computational Biology and is located in San Diego, California.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 276MS.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.